References
- National Safety Council. Prescription Nation 2016: Addressing America’s Drug Epidemic. 2016. [cited 2017 Nov 14]. Available from: http://www.nsc.org/RxDrugOverdoseDocuments/Prescription-Nation-2016-American-Drug-Epidemic.pdf.
- Centers for Disease Control and Prevention. Opioid Overdose. Prescription Opioid Overdose Data. 2016. [cited 2018 Mar 20]. Available from: https://www.cdc.gov/drugoverdose/data/overdose.html.
- Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14:351–358.
- Vietri J, Joshi AV, Barsdorf AI, et al. Prescription opioid abuse and tampering in the United States: results of a self-report survey. Pain Med. 2014;15:2064–2074.
- Surratt H, Kurtz SP, Cicero TJ. Alternate routes of administration and risk for HIV among prescription opioid abusers. J Addict Dis. 2011;30:334–341.
- Bucher Bartelson B, Le Lait MC, Dart R, et al. Medical outcomes associated with unintended routes of prescription opioid abuse. Postgrad Med. 2015;127:S54–55.
- Food and Drug Administration. Abuse-Deterrent Opioids – Evaluation and Labeling. Guidance for Industry. 2015. [cited 2018 Mar 20]. Available from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf.
- Califf RM, Woodcock J, Ostroff S. A proactive response to prescription opioid abuse. N Engl J Med. 2016;374:1480–1485.
- Rossiter LF, Kirson NY, Shei A, et al. Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US. J Med Econ. 2014;17:279–287.
- Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22:1274–1282.
- Coplan P, Kadakia A. Changes in diagnosed addiction rates in patients prescribed opioids after introduction of oxycontin with abuse-deterrent properties. College on Problems of Drug Dependence. 77th Annual Meeting:34. 2015.
- Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14:1122–1130.
- Chilcoat H, Coplan P, Sessler N, et al. Impact of an opioid reformulation with abuse-deterrent properties on doctor-shopping. J Pain. 2014;15:S10.
- Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;372:241–248.
- Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: lessons learned from oxycontin. JAMA Psychiatry. 2015;72:424–430.
- Dart RC, Iwanicki JL, Dasgupta N, et al. Do abuse deterrent opioid formulations work? J Opioid Manag. 2017;13:365–378.
- Lebin JA, Murphy DL, Severtson SG, et al. Scoring the best deal: quantity discounts and street price variation of diverted oxycodone and oxymorphone. Pharmacoepidemiol Drug Saf. 2018.